Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate

Abstract
Purpose: Clinical evaluation of novel agents that target tumor blood vessels requires pharmacodynamic end points that measure vascular damage. Positron emission tomography (PET) was used to measure the effects of the vascular targeting agent combretastatin A4 phosphate (CA4P) on tumor and normal tissue perfusion and blood volume.

This publication has 21 references indexed in Scilit: